Endologix, Inc. is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. The Company's product offering includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Designed around key issues with challenging anatomies, difficult access, and aneurysm sealing, Endologix products have been clinically proven in delivering positive patient outcomes.
Type | Public | |
Founded | 1992 | |
HQ | Irvine, CA, US | Map |
Website | endologix.com | |
Employee Ratings |
USD | |
---|---|
Revenue (Q2, 2020) | 24.8m |
Gross profit (Q2, 2020) | 14.2m |
Gross profit margin (Q2, 2020), % | 57% |
Net income (Q2, 2020) | (26.1m) |
EBIT (Q2, 2020) | (17.3m) |
Market capitalization (1-Oct-2020) | 4.2m |
Closing stock price (1-Oct-2020) | 0.0 |
Cash (30-Jun-2020) | 18.5m |
EV | 382.2m |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 42.6m | 48.6m | 46.0m | 42.3m | 44.7m | 34.8m | 35.6m | 36.2m | 35.8m | 28.5m | 24.8m |
Cost of goods sold | 14.0m | 16.3m | 16.9m | 14.0m | 15.1m | 12.1m | 12.4m | 13.3m | 12.7m | 13.4m | 10.7m |
Gross profit | 28.6m | 32.2m | 29.1m | 28.3m | 29.6m | 22.6m | 23.2m | 23.0m | 23.1m | 15.1m | 14.2m |
Gross profit Margin, % | 67% | 66% | 63% | 67% | 66% | 65% | 65% | 63% | 64% | 53% | 57% |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (21.3m) | (37.6m) | (51.9m) | (19.8m) | (43.6m) | (53.8m) | (22.0m) | (49.2m) | (56.9m) | (18.1m) | (44.2m) |
Depreciation and Amortization | 2.3m | 4.6m | 6.9m | 2.0m | 3.9m | 5.9m | 1.7m | 3.5m | 5.3m | 1.2m | 2.9m |
Inventories | (1.5m) | (2.2m) | (1.0m) | (784.0k) | 1.8m | 2.1m | 112.0k | (463.0k) | (768.0k) | 1.8m | 339.0k |
Accounts Payable | (4.5m) | (3.5m) | (3.4m) | 391.0k | 809.0k | (1.0m) | 5.4m | 1.7m | 886.0k | (1.4m) | (5.1m) |
USD | FY, 2016 |
---|---|
Revenue/Employee | 246.7k |
Financial Leverage | 3.2 x |
Endologix has 994 Twitter Followers. The number of followers has increased 1% month over month and increased 1.5% quarter over quarter
686
Tweets
1.1k
Following
994
Followers
12
Tweets last 30 days
5.8
Avg. likes per Tweet
100%
Tweets with engagement
When was Endologix founded?
Endologix was founded in 1992.
Who are Endologix key executives?
Endologix's key executives are John Onopchenko, Cindy Pinto and Reyna Fernandez.
How many employees does Endologix have?
Endologix has 528 employees.
What is Endologix revenue?
Latest Endologix annual revenue is $143.4 m.
What is Endologix revenue per employee?
Latest Endologix revenue per employee is $271.5 k.
Who are Endologix competitors?
Competitors of Endologix include CSL, Mcneil and The Searle Company.
Where is Endologix headquarters?
Endologix headquarters is located at 2 Musick, Irvine.
Where are Endologix offices?
Endologix has offices in Irvine, Santa Rosa, Rosmalen, 's-Hertogenbosch and in 1 other location.
How many offices does Endologix have?
Endologix has 5 offices.
Receive alerts for 300+ data fields across thousands of companies